The scientific observatories on Mont Blanc

The invention of hypoxia

The word "hypoxia" has recently come to the attention of the general public on two occasions, the Nobel Prize in Medicine or Physiology in 2019 and the recent COVID-19 pandemic. In the academic environment, hypoxia is a current topic of research in biology, physiology, and medicine: in October 2020, there were more than 150,000 occurrences of "hypoxia" in the PubMed database. However, the first occurrence is dated to 1945, while the interest for the effects of oxygen lack on the living organisms started in the mid-19th century, when scientists explored high altitude regions and mainly used the terms "anoxia" or "anoxemia." I therefore researched online through multiple databases to look for the first appearance of "hypoxia" and related terms "hypoxemia" and "hypoxybiosis" in scientific literature published in English, German, French, Italian, and Spanish. Viault and Jolyet used "Hypohématose" in 1894, but this term has not been used since. Hypoxybiosis first appeared in 1909 in Germany, then hypoxemia in 1923 in Austria, and hypoxia in 1938 in Holland. It was then exported to the United States where it appeared in 1940 in cardiology and anesthesiology. The clinical distinction between anoxia and hypoxia was clearly defined by Carl Wiggers in 1941. Hypoxia (decrease in oxygen), by essence variable in time and in localization in the body, in contrast with anoxia (absence of oxygen), illustrates the concept of homeodynamics that defines a living organism as a complex system in permanent instability, exposed to environmental and internal perturbations.

Research at high altitudes

Science and mountain exploration are closely linked throughout history. A large array of studies of varying complexity have been performed in conditions of hypobaric hypoxia, some on field studies, some in hypobaric chambers. The military has contributed greatly to this body of evidence both through operations in high altitude regions of the world, hypobaric chamber studies and through field studies as part of adventurous training expeditions. The hope is that by investigating hypoxia in fit participants in field or chamber studies insights may be gained into the adaptation to hypoxia during critical illness and novel approaches for treatment developed. Field studies in the mountains are challenging to design and undertake and need to balance practicalities (e.g. limited power supply) with scientific objectives. This article examines the history and rationale for high altitude research and discusses the challenges of organising a field study.

Sildenafil inhibits altitude-induced hypoxemia and pulmonary hypertension

Exposure to high altitude induces pulmonary hypertension that may lead to life-threatening conditions. In a randomized, double-blind, placebo-controlled study, the effects of oral sildenafil on altitude-induced pulmonary hypertension and gas exchange in normal subjects were examined. Twelve subjects (sildenafil [SIL] n = 6; placebo [PLA] n = 6) were exposed for 6 days at 4,350 m. Treatment (3 x 40 mg/day) was started 6 to 8 hours after arrival from sea level to high altitude and maintained for 6 days. Systolic pulmonary artery pressure (echocardiography) increased at high altitude before treatment (+29% versus sea level, p < 0.01), then normalized in SIL (-6% versus sea level, NS) and remained elevated in PLA (+21% versus sea level, p < 0.05). Pulmonary acceleration time decreased by 27% in PLA versus 6% in SIL (p < 0.01). Cardiac output and systemic blood pressures increased at high altitude then decreased similarly in both groups. Pa(O(2)) was higher and alveolar-arterial difference in O(2) lower in SIL than in PLA at rest and exercise (p < 0.05). The altitude-induced decrease in maximal O(2) consumption was smaller in SIL than in PLA (p < 0.05). Sildenafil protects against the development of altitude-induced pulmonary hypertension and improves gas exchange, limiting the altitude-induced hypoxemia and decrease in exercise performance.